Skip to content

The Relationship Between Moderate-to-severe Psoriasis and Sleep Disturbance

The Relationship Between Moderate-to-severe Psoriasis and Sleep Disturbance: a Prospective Cohort Study

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06165887
Enrollment
156
Registered
2023-12-12
Start date
2024-02-29
Completion date
2026-06-30
Last updated
2024-02-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Moderate-to-severe Psoriasis

Brief summary

Psoriasis is a common chronic and systemic immune-mediated disease, induced by a combination of genetic and environmental effects. The increasingly worrying question is the negative impact on patients' sleep, which has become an important comorbidity of psoriasis. To investigate the causal relationship between psoriasis and sleep status, a prospective cohort study will be conducted by separating moderate-to-severe psoriasis patients and healthy individuals into distinct cohorts in order to observe their sleep status.

Detailed description

Target follow-up duration for the study is 24 weeks, during which participants will undergo a sleep monitoring session every 8 weeks. The sleep monitoring data collected includes time to fall asleep, time to bed, sleep perception, and the Pittsburgh Sleep Quality Index (PSQI). The Dermatology Quality of Life Index (DLQI), the Psoriasis Area and Severity Index (PASI), and the Visual Analog Scale (VAS) will simultaneously be used to assess the severity of the disease in the cohort of patients with psoriasis.

Interventions

OTHERNo intervention

This is an observational study, no intervention will be implemented.

Sponsors

Shanghai Yueyang Integrated Medicine Hospital
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

1. In line with the diagnostic criteria of psoriasis 2. PASI\>10 or BSA\>10% 3. Understand and agree to participate in this study and sign the informed consent.

Exclusion criteria

1. Those with serious mental diseases, such as depression, anxiety, etc; 2. PSQI\>5 points; 3. Long term use of sedative and hypnotic drugs; 4. Patients with diabetes mellitus or severe heart, liver and kidney disease; 5. Those diagnosed with sleep disorders, such as apnea syndrome, periodic limb movement disorder, restless legs syndrome, narcolepsy, etc; 6. There are serious cardiovascular and cerebrovascular diseases, respiratory system diseases, and immune system diseases; 7. Pregnant women during pregnancy, lactation, or planned trials; 8. Those who have participated in other clinical studies or are participating in other clinical trials within 3 months; 9. Unable to cooperate with the study for any reason, such as the following situation: language understanding, unable to complete the scale tester. If any one of the above items is met, it shall be excluded.

Design outcomes

Primary

MeasureTime frameDescription
Pittsburgh sleep quality index (PSQI)week0、week8、week16、week24PSQI is a 19-item self-rated questionnaire for evaluating subjective sleep quality over the previous month. A score above 5 suggests poor sleep quality.

Secondary

MeasureTime frameDescription
Psoriasis Area and Severity Index (PASI)week0、week8、week16、week24The PASI score ranges from 0 to 72, and the higher the score, the more serious the patient's condition. Generally speaking, a PASI score of less than 10 indicates mild psoriasis, 10-20 indicates moderate psoriasis, and more than 20 indicates severe psoriasis.
Dermatology Life Quality Index (DLQI)week0、week8、week16、week24DLQI was a participant-reported questionnaire used to measure the health-related quality of life (QOL) of adults suffering from a skin disease. Scores ranged from 0-30, a higher score indicating a greater impact on a participant's QOL.
Visual Analogue Scale (VAS)week0、week8、week16、week24The scoring criteria for pruritus level are as follows: absence of pruritus = 0; mild (intermittent itching, no scratching, no interference with daily activities) = 1-3 points; moderate (frequent itching, occasional scratching, impacting daily routine and sleep) = 4-6 points, and severe (intense itching, persistent scratching, significantly affecting daily life and sleep) = 7-10 points.
Hospital Anxiety and Depression Scale(HADS)week0、week8、week16、week24For describing depression and anxiety in hospital patients

Countries

China

Contacts

Primary ContactXin Li, PHD
13661956326@163.com13661956326
Backup ContactPengbo Gao, bachelor
13584213753@163.com13584213753

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026